Menu Search
Equities

Fulgent Genetics Inc

FLGT:NMQ

Fulgent Genetics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)18.32
  • Today's Change0.445 / 2.49%
  • Shares traded301.58k
  • 1 Year change-34.43%
  • Beta1.4372
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Fulgent Genetics Inc's revenues fell -53.27% from 618.97m to 289.21m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 143.40m to a loss of 167.83m.
Gross margin36.22%
Net profit margin-61.91%
Operating margin-78.84%
Return on assets-13.27%
Return on equity-13.76%
Return on investment-14.00%
More ▼

Cash flow in USDView more

In 2023, Fulgent Genetics Inc increased its cash reserves by 22.60%, or 17.97m. Cash Flow from Investing totalled 38.90m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 27.00m in cash from operations while cash used for financing totalled 47.79m.
Cash flow per share-4.89
Price/Cash flow per share--
Book value per share37.28
Tangible book value per share32.07
More ▼

Balance sheet in USDView more

Fulgent Genetics Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.08%.
Current ratio4.41
Quick ratio--
Total debt/total equity0.0008
Total debt/total capital0.0008
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.